Oncotarget– Publishing Latest Oncology Research Findings
Oncotarget is a free-access multidisciplinary traditional research journal. The mission of the journal is to make important scientific results widely and rapidly available. The journal publishes online papers weekly. The Oncotarget success has prompted the publishers to launch sections that are now going beyond oncology such as Cell Biology, Neuroscience, Cardiology, Endocrinology, Metabolism, Pharmacology and more.
New EPOC Study
IntegraGen has announced that study outcomes from an investigation of miR-31-3p expression from patients enrolled in this clinical trial have now been published in Oncotarget (November 2017). Tumor samples were used in the analysis. This publication has confirmed that analyzing expression levels in patients suffering from RAS wild-type metastatic colorectal cancer may be utilized as a complementary diagnostic tool towards helping in identifying those who stand to gain from targeted anti-EGFR therapy.
This is the first theranosticpositive test for metastatic colorectal cancer (mCRC) patients. The New EPOC Study data will provide additional insights to clinicians on therapeutic approaches tailoring for better treatment outcomes for metastatic colorectal cancer patients.
Ovarian Cancer Circulating Tumor Cells Study
Amongst gynecological cancers, ovarian cancer is rated as the most common causes of death globally. The majority of cases are usually diagnosed during their late-stage leading to poor survival. This study concluded that there is available evidence supporting the view that CTCs/DTCs were associated significantly with advanced ovarian cancer tumor stage, other residual diseases as well as treatment response. This, however, was not the case with histological types or with lymph node metastasis for patients having ovarian cancer.
In addition, CTCs were significantly linked to poorer survival. The study concluded that CTCs/DTCs could be employed as a dependable non-invasive prognostic indicator for ovarian cancer. Therefore, clinical management on the basis of CTCs/DTCs may be beneficial when it comes determining which ovarian cancer patients potentially stand gain from adjuvant therapy.
A research journal publication, Oncotarget is accessible to medics who think they can contribute information. Covering deep oncology research, this is an outstanding and very important journal in the field of cancer research. Established in 2010, Oncotarget is published by Impact Journals and is also ranked by Scimago Journal.